Psychotic symptoms such as visual hallucinations and delusions are a relatively common clinical problem in patients with Parkinson's disease (PD). A dilemma arises in the treatment of psychosis in these patients because traditional antipsychotics are dopaminergic antagonists that worsen the motor symptoms of PD. Clozapine, an atypical antipsychotic, has been successfully used in the treatment of psychosis in PD patients. The use of clozapine in these patients differs significantly, however, from its use in young, relatively healthy, treatment-resistant schizophrenic patients in the dosage required, side effects, and other aspects of management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/jnp.8.1.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Compulsory care for a mental incompetent pregnant woman: a case-report].
Tijdschr Psychiatr
January 2025
The compulsory Mental Healthcare Act (Dutch: Wvggz) provides, in exceptional cases, a legal framework for the implementation of psychiatric and somatic treatment without the patients consent. We describe a pregnant patient with a psychotic disorder who was compulsorily admitted to a psychiatric ward and treated with antipsychotic medication. She was unable to give informed consent regarding obstetric care.
View Article and Find Full Text PDFPalmitoylethanolamide supplementation for human health: A state-of-the-art systematic review of Randomized Controlled Trials in patient populations.
Brain Behav Immun Health
February 2025
Unit of Psychiatry and Eating Disorders, Department of Medicine (DMED), University of Udine, Udine, Italy.
Interest in preventative dietary interventions for human health has increasingly focused on the endocannabinoid (eCB)-like compound palmitoylethanolamide (PEA), a bioactive lipid mediator with anti-inflammatory, analgesic, and neuroprotective properties. This Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020-compliant systematic review aimed at collecting and comprehensively discussing all available data from Randomized Controlled Trials (RCTs) evaluating the efficacy and tolerability of PEA supplementation across human illnesses in patient populations. Overall, 48 eligible outputs from 47 RCTs were extracted, covering neuropsychiatric ( = 15), neurological ( = 17), somatic ( = 13), and visceral ( = 11) disturbances, as well as PEA effects on blood/plasma or other tissue biomarkers ( = 10).
View Article and Find Full Text PDFShould we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis.
Brain Behav Immun Health
February 2025
Oswaldo Cruz Foundation, Institute Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
Schizophrenia is a chronic psychiatric disorder characterized by a variety of symptoms broadly categorized into positive, negative, and cognitive domains. Its etiology is multifactorial, involving a complex interplay of genetic, neurobiological, and environmental factors, and its neurobiology is associated with abnormalities in different neurotransmitter systems. Due to this multifactorial etiology and neurobiology, leading to a wide heterogeneity of symptoms and clinical presentations, current antipsychotic treatments face challenges, underscoring the need for novel therapeutic approaches.
View Article and Find Full Text PDFPolygenic risk scores for atrial fibrillation and heart failure and the risk of stroke and dementia.
Brain Commun
January 2025
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Centre for Ageing and Health (AgeCap) at the University of Gothenburg, Mölndal 43139, Sweden.
Atrial fibrillation and heart failure have both been suggested to increase stroke and dementia risk. However, in observational studies, reversed causation and unmeasured confounding may occur. To mitigate these issues, this study aims to investigate if higher genetic risk for atrial fibrillation and heart failure increases dementia and stroke risk.
View Article and Find Full Text PDFApplied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol.
Front Psychiatry
January 2025
Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPs), Barcelona, Spain.
The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!